Research.Patient.info

Pancreatic ductal adenocarcinoma research hub

1 indexed studies · 0 currently recruiting

ongoing, recruitingTherapeutic exploratory (Phase II)
Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours
Spain · France · Belgium